LaBel addresses the possibility of getting further into the cochlea with phase 2a dosing:
https://www.fiercebiotech.com/biotech/frequency-s-hearing-loss-treatment-shows-long-term-promise
"FX-322 is two small-molecule drugs and once injected, they essentially diffuse into the inner ear. We can imagine a wave of two drugs washing through a particular region of the cochlea," LeBel said. "One week later, we come back. Maybe that second injection gets a bit further throughout the cochlea, maybe it hits an additional number of progenitor cells and we get a bigger benefit. Or, maybe with additional injections, we will get more people with the same benefit. We don't know which it might be—that's the reason we designed it this way."
https://www.fiercebiotech.com/biotech/frequency-s-hearing-loss-treatment-shows-long-term-promise
"FX-322 is two small-molecule drugs and once injected, they essentially diffuse into the inner ear. We can imagine a wave of two drugs washing through a particular region of the cochlea," LeBel said. "One week later, we come back. Maybe that second injection gets a bit further throughout the cochlea, maybe it hits an additional number of progenitor cells and we get a bigger benefit. Or, maybe with additional injections, we will get more people with the same benefit. We don't know which it might be—that's the reason we designed it this way."